Compare SSBI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | EQ |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 89.4M |
| IPO Year | N/A | 2018 |
| Metric | SSBI | EQ |
|---|---|---|
| Price | $11.39 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 2.8K | ★ 344.2K |
| Earning Date | 10-27-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $1.16 |
| 52 Week High | $14.00 | $6.20 |
| Indicator | SSBI | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 53.88 |
| Support Level | $11.36 | $1.30 |
| Resistance Level | $13.59 | $2.53 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 7.38 | 79.55 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.